OncoHost Overview
OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. The company aims to understand the patient's unique response to therapy to overcome one of the major obstacles in clinical oncology today – resistance to treatment. OncoHost developed the PROphet platform. Combining bioinformatics, system biology, proteomic pattern recognition and machine learning, PROphet provides clinicians with actionable clinical insights, optimal choice of therapy, and a better understanding of their patients' personalized cancer dynamics.
Cumulative Funding Raised Over Time ($)
—Dec 2023
$8.0MJan 2021
$8.0MMar 2024
$13.0MMay 2019
$48.0MMay 2022
$49.6MOct 2017
Latest News
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine through plasma proteomics and AI, today announced that it has...
OncoHost, a technology company specializing in precision medicine through plasma proteomics and AI, has received a laboratory permit from the New York State Department of Health Wadsworth Center. This permit allows OncoHost to offer its PROphetNSCLC® test to physicians and patients across New York State, marking a significant milestone in the companys U.S. expansion. The PROphetNSCLC® test, part of OncoHosts AI-powered proteomic profiling platform, is designed to guide first-line treatment decisions in oncology, specifically for metastatic non-small cell lung cancer. The test is now available for clinical use in all 50 U.S. states, enhancing OncoHosts clinical reach and supporting oncologists in making data-driven treatment decisions.
Product StageCustomers
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that its latest...
OncoHost, a technology company focused on precision medicine, announced that its research will be presented at the ESMO 2025 Congress. The study highlights the use of OncoHosts PROphet® model, a plasma proteomics-based tool, to optimize treatment decisions for metastatic melanoma. The model, initially developed for non-small cell lung cancer, has shown predictive value in guiding treatment for melanoma patients. The study found that PROphet® can stratify patients effectively, with PROphet POSITIVE patients showing a significant survival advantage. This research underscores the models potential to inform treatment decisions and enhance personalized care for melanoma patients. OncoHost is positioned to advance precision diagnostics and biomarker development.
growth-positive
/PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to personalize cancer care, today announced its selection as the Top...
OncoHost, a leader in precision oncology, has been recognized as the Top Precision Oncology Solution for 2025 by Life Sciences Review. This accolade underscores the impact of OncoHosts flagship platform, PROphet®, an AI-powered decision-support tool that enhances immunotherapy planning by predicting clinical benefits and potential toxicities. The platforms first clinical application, PROphetNSCLC™, aids in treatment decisions for advanced non-small cell lung cancer. OncoHost is expanding its platform with additional products like PROphetirAE™, PROphetRCC™, and PROphetMELANOMA™. The recognition highlights OncoHosts commitment to transforming cancer care by focusing on the patients full biological context rather than just tumor biology.
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision oncology through proteomics and AI, today announced the publication of a...
OncoHost, a technology company specializing in precision oncology, has published a study in the Journal for ImmunoTherapy of Cancer. The study focuses on understanding resistance to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) through plasma proteomics and AI. By analyzing pretreatment plasma proteomic profiles from 272 NSCLC patients, the study identifies key biological processes associated with resistance and potential therapeutic targets. OncoHosts PROphet® platform, an AI-powered decision-support tool, plays a crucial role in this research. The findings could lead to personalized treatment strategies, improving the efficacy of existing immunotherapies and reducing exposure to ineffective treatments. OncoHost is conducting a large-scale clinical trial to further validate its platform.
Product Stage
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its...
OncoHost, a technology company focused on precision medicine, announced that three of its research abstracts have been accepted for presentation at the 2025 ASCO Annual Meeting. The studies cover various cancer types and highlight the clinical utility of plasma proteomics in advancing personalized treatment strategies. OncoHosts platform, PROphet®, uses plasma-based proteomic pattern analysis to guide immunotherapy decisions in non-small cell lung cancer (NSCLC). The company is actively involved in a large-scale clinical trial and is well-positioned to lead in precision diagnostics and biomarker development. The participation in ASCO 2025 marks a significant milestone for OncoHost, reinforcing its commitment to improving patient outcomes through advanced proteomic technologies and AI-driven analytics.
Product StageCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $53.4M |
| Last funding | $2.8M |
| Stage | C |
| Rounds | 8 |
| Investors | 7 |
Team Members
13
Employees: 11-50
Web & Social Links
| Website | www.oncohost.com |
| Careers | Careers page |
Locations
HaMelacha St 17, Binyamina-Giv'at Ada, Israel
1110 SE Cary Pkwy, Cary, NC 27518, USA
Photos & Videos
1 item(s)
OncoHost Business
Business models
B2B2C, B2B, B2C
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesHealthcareInsurance CompaniesProvidersPatientsLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesArtificial IntelligenceMachine LearningTags (17)
pharmaceuticalsoncologycancerpersonalized-medicinediagnosticsdata-analyticsartificial-intelligenceblood-testmachine-learningcancer-therapybioinformaticstreatmentsdecision-supportdigital-healthcarebioconvergenceimmunotherapyclinical-trialsGeographic Markets
IsraelUnited KingdomUnited StatesOncoHost Financials
$53.4M
Total funding
Undisclosed
Capital raised
$2.8M
Last funding
C
Funding stage
8
Total rounds
7
Investors
Cumulative Funding Raised Over Time ($)
—Dec 2023
$8.0MJan 2021
$8.0MMar 2024
$13.0MMay 2019
$48.0MMay 2022
$49.6MOct 2017
Private Equity Funding
SAFE
Mar 2024
Undisclosed
OurCrowd
SAFE
Dec 2023
Undisclosed
OurCrowd
C Round
May 2022
$35M
ALIVE Israel Healthtech Fund (Lead)
,
OurCrowd, Menora Mivtachim Insurance, Together We Invest, Leumi Partners
B Round
Jan 2021
$8M
OurCrowd (Lead)
A Round
May 2019
$5M
CMEH, Om Maya
Seed
Oct 2017
$1.6M
Om Maya (Lead)
Non-Equity Funding
GrantEvent
May 2025
$2.8M
EIC Accelerator (Lead)
GrantEvent
Jan 2020
$1M
BIRD Foundation
OncoHost Lifecycle
Cumulative Funding Raised Over Time
—Dec 2023
$8.0MJan 2021
$8.0MMar 2024
$13.0MMay 2019
$48.0MMay 2022
$49.6MOct 2017
All Events
SAFE
Mar 2024
Undisclosed
OurCrowd
SAFE
Dec 2023
Undisclosed
OurCrowd
C Round
May 2022
$35M
ALIVE Israel Healthtech Fund (Lead)
,
OurCrowd, Menora Mivtachim Insurance, Together We Invest, Leumi Partners
B Round
Jan 2021
$8M
OurCrowd (Lead)
A Round
May 2019
$5M
CMEH, Om Maya
Seed
Oct 2017
$1.6M
Om Maya (Lead)
GrantEvent
May 2025
$2.8M
EIC Accelerator (Lead)
GrantEvent
Jan 2020
$1M
BIRD Foundation
OncoHost News
43 articles
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine through plasma proteomics and AI, today announced that it has...
OncoHost, a technology company specializing in precision medicine through plasma proteomics and AI, has received a laboratory permit from the New York State Department of Health Wadsworth Center. This permit allows OncoHost to offer its PROphetNSCLC® test to physicians and patients across New York State, marking a significant milestone in the companys U.S. expansion. The PROphetNSCLC® test, part of OncoHosts AI-powered proteomic profiling platform, is designed to guide first-line treatment decisions in oncology, specifically for metastatic non-small cell lung cancer. The test is now available for clinical use in all 50 U.S. states, enhancing OncoHosts clinical reach and supporting oncologists in making data-driven treatment decisions.
Product StageCustomers
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that its latest...
OncoHost, a technology company focused on precision medicine, announced that its research will be presented at the ESMO 2025 Congress. The study highlights the use of OncoHosts PROphet® model, a plasma proteomics-based tool, to optimize treatment decisions for metastatic melanoma. The model, initially developed for non-small cell lung cancer, has shown predictive value in guiding treatment for melanoma patients. The study found that PROphet® can stratify patients effectively, with PROphet POSITIVE patients showing a significant survival advantage. This research underscores the models potential to inform treatment decisions and enhance personalized care for melanoma patients. OncoHost is positioned to advance precision diagnostics and biomarker development.
growth-positive
/PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to personalize cancer care, today announced its selection as the Top...
OncoHost, a leader in precision oncology, has been recognized as the Top Precision Oncology Solution for 2025 by Life Sciences Review. This accolade underscores the impact of OncoHosts flagship platform, PROphet®, an AI-powered decision-support tool that enhances immunotherapy planning by predicting clinical benefits and potential toxicities. The platforms first clinical application, PROphetNSCLC™, aids in treatment decisions for advanced non-small cell lung cancer. OncoHost is expanding its platform with additional products like PROphetirAE™, PROphetRCC™, and PROphetMELANOMA™. The recognition highlights OncoHosts commitment to transforming cancer care by focusing on the patients full biological context rather than just tumor biology.
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision oncology through proteomics and AI, today announced the publication of a...
OncoHost, a technology company specializing in precision oncology, has published a study in the Journal for ImmunoTherapy of Cancer. The study focuses on understanding resistance to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) through plasma proteomics and AI. By analyzing pretreatment plasma proteomic profiles from 272 NSCLC patients, the study identifies key biological processes associated with resistance and potential therapeutic targets. OncoHosts PROphet® platform, an AI-powered decision-support tool, plays a crucial role in this research. The findings could lead to personalized treatment strategies, improving the efficacy of existing immunotherapies and reducing exposure to ineffective treatments. OncoHost is conducting a large-scale clinical trial to further validate its platform.
Product Stage
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its...
OncoHost, a technology company focused on precision medicine, announced that three of its research abstracts have been accepted for presentation at the 2025 ASCO Annual Meeting. The studies cover various cancer types and highlight the clinical utility of plasma proteomics in advancing personalized treatment strategies. OncoHosts platform, PROphet®, uses plasma-based proteomic pattern analysis to guide immunotherapy decisions in non-small cell lung cancer (NSCLC). The company is actively involved in a large-scale clinical trial and is well-positioned to lead in precision diagnostics and biomarker development. The participation in ASCO 2025 marks a significant milestone for OncoHost, reinforcing its commitment to improving patient outcomes through advanced proteomic technologies and AI-driven analytics.
Product StageCustomers
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, together with its esteemed...
OncoHost, a technology company focused on precision medicine, has been awarded a €2.5 million grant from the EIC Transition Program of Horizon Europe. The grant will support the development of a novel biomarker for predicting response to immunotherapy across five cancer indications. OncoHost is collaborating with Heidelberg University Hospital, European Institute of Oncology, and Virgen Macarena University Hospital. The consortium aims to develop NeutroFlow, a rapid point-of-care test for predicting treatment response. This initiative underscores OncoHosts commitment to advancing precision medicine and improving patient outcomes through innovative biomarker development.
PartnersInvestment
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved cancer patient outcomes, today announced its...
OncoHost, a technology company focused on precision medicine, announced its acceptance to present a scientific poster at the AACR Annual Meeting 2025. The poster will discuss the PROphetNSCLC™ model, a treatment guidance tool for advanced non-small cell lung cancer (NSCLC) patients. The study, conducted in collaboration with leading cancer centers, identifies resistance-associated proteins (RAPs) that can help stratify patients and identify new therapeutic targets. The findings suggest that RAPs can serve as novel targets for intervention, enhancing the clinical significance of these proteins. OncoHosts platform, PROphet®, uses plasma-based proteomic pattern analysis to guide immunotherapy decision-making, supported by a large-scale clinical trial. The companys work is positioned to advance precision diagnostics and biomarker development.
Product StageCustomers
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration...
OncoHost, a technology company focused on precision medicine, has partnered with Gustave Roussy, a leading European cancer center, to conduct the PREMIS study. This study aims to identify non-invasive biomarkers for immune-related adverse events (irAEs) in patients undergoing immunotherapy. The collaboration seeks to validate OncoHosts PROphetirAE™ test, which uses AI and biomarker analysis to predict patient risk for irAEs. The study involves 1,000 cancer patients and aims to improve patient safety and treatment outcomes by personalizing immunotherapy strategies. This partnership is a significant step in addressing the challenges of predicting irAEs and optimizing therapeutic approaches.
Partners
growth-positive
/PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology dedicated to advancing personalized cancer therapy, announced today that it has...
OncoHost, a leader in precision oncology, has been recognized with the 2025 BIG Innovation Award in the Healthcare category for its PROphet® platform. This platform addresses the challenge of finding reliable biomarkers for immunotherapy treatment decisions, offering personalized insights to improve patient outcomes. The PROphetNSCLC™ test is the first AI-based blood test for guiding immunotherapy in metastatic non-small cell lung cancer. OncoHost is also developing the PROphetirAE test to predict immune-related adverse events, enhancing patient care. The award highlights OncoHosts commitment to advancing oncology and healthcare innovation.
Product Stage
growth-positive
/PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology dedicated to advancing personalized cancer therapy, announced today that it has...
OncoHost, a leader in precision oncology, has been recognized with the 2025 BIG Innovation Award in the Healthcare category. The company’s PROphet® platform addresses the lack of reliable biomarkers in immunotherapy by providing personalized insights to guide treatment decisions. The platforms PROphetNSCLC™ test is the first AI-based blood test for metastatic non-small cell lung cancer, and it shows promise for other cancers. OncoHost is also developing the PROphetirAE test to predict immune-related adverse events. This recognition highlights OncoHosts commitment to advancing oncology and improving patient care through innovative solutions.
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, announced today that its...
OncoHost, a technology company focused on precision medicine, announced that its high-throughput proteomics laboratory in Cary, North Carolina, has received accreditation from the College of American Pathologists (CAP). This accreditation highlights OncoHosts commitment to quality and safety in laboratory practices. The Cary facility is one of the few specialized labs dedicated to human host response analysis. OncoHosts proprietary PROphet® platform uses proteomic pattern recognition to support clinical decision-making in cancer care, allowing for personalized treatment plans. The CAP accreditation is a significant milestone for OncoHost, reinforcing its mission to provide high-quality, innovative solutions in precision oncology. The company is well-positioned to lead advancements in precision diagnostics and biomarker development.
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that Ron Andrews...
OncoHost, a technology company focused on precision medicine, has appointed Ron Andrews as a Strategic Consultant to the CEO. Andrews, with over 35 years of experience in the diagnostics industry, will aid in accelerating OncoHosts growth and expansion initiatives. His extensive background includes leadership roles at major companies like Abbott Diagnostics and Roche Molecular Diagnostics. Andrews is expected to provide strategic insights and leadership to help OncoHost advance its precision oncology field. The companys proprietary platform, PROphet®, is designed to guide immunotherapy decisions in non-small cell lung cancer, enhancing patient outcomes. Andrews appointment is seen as a positive step towards scaling the companys innovative solutions globally.
Management Changes
growth-positive
/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced its selection to...
OncoHost, a technology company specializing in precision medicine, announced its selection to present a poster at the European Society of Medical Oncology (ESMO) Congress 2024. The research, conducted in collaboration with Dana-Farber Cancer Institute, extends the application of OncoHosts PROphet® platform from non-small cell lung cancer (NSCLC) to renal cell carcinoma (RCC). The study demonstrated that the platform could predict clinical outcomes and improve overall survival and progression-free survival in RCC patients. This milestone highlights the versatility of the PROphet® platform and its potential for broader applications in various cancer types.
Partners
growth-positive
OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
OncoHost, a technology company focused on precision medicine, has announced a research study in collaboration with Dana-Farber Cancer Institute. The study aims to identify biomarkers for renal cell carcinoma (RCC), a type of kidney cancer. The collaboration will use Dana-Farbers repository of patient plasma samples and clinical data, allowing OncoHost to create a proteomic plasma profile. The primary objectives of the study include creating a proteomic plasma profile of metastatic RCC patients before treatment, associating protein expression changes with treatment response metrics, and evaluating differential response predictions to specific treatment combinations.
Partners
growth-positive
AI Tool Helps Doctors Pick Optimum Cancer Treatment For Patients
Israeli medtech company OncoHost is using artificial intelligence to help oncologists decide the best treatment for their cancer patients. The companys proprietary PROphet platform uses AI to scan up to 7,000 proteins in a patients blood to determine how receptive they would be to immunotherapy. The platform can also help doctors decide whether to pursue immunotherapy as a sole treatment or to combine it with chemotherapy. The company is currently conducting clinical trials in 40 locations in Europe, Israel, and the US. OncoHost is privately funded by venture capital investors.
Investment
growth-positive
Henlius and OncoHost partner to predict trial outcomes using machine learning
Hengenix Biotech has partnered with OncoHost to perform biomarker analysis and predict clinical benefit probability in patients recruited for the Phase III clinical trial for serplulimab, a drug for small-cell lung cancer. OncoHosts PROphet platform will be used to analyze the patients biomarkers to identify resistance patterns. The platform uses AI and machine learning models for patient selection, survival prediction, mechanisms of action discovery, adverse events prediction, and response prediction.
PartnersCustomers
New Israeli technology improves prediction of patient response to immunotherapy
growth-positive
OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment
OncoHost, a technology company focusing on precision medicine, has announced its plans to present the accuracy of its PROphet biomarker model at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023. The PROphet model, which is based on a plasma proteomic pattern analysis tool, is designed to guide first-line immunotherapy decision-making for advanced non-small cell lung cancer (NSCLC) patients. The model has been trained on OncoHosts large-scale clinical trial, PROPHETIC, which has recruited over 1,700 patients across 40 sites worldwide.
CustomersPartners
growth-positive
Blood Test Offers Hope For Lung Cancer Patients
Israeli company OncoHost has developed a blood test that scans proteins in a patients blood plasma to predict their clinical benefit from immunotherapy-based treatment for lung cancer. The test will help determine the best treatment options for patients who cannot undergo surgery. OncoHosts algorithm, developed during an ongoing clinical trial, has already predicted treatment plans for 1,500 patients. The company believes the test will have a significant impact on patient care and treatment protocols by offering personalized insights on the predicted clinical benefit of immunotherapy. OncoHost was founded in 2017 and is based in Binyamina, northern Israel.
Customers
growth-positive
OncoHost Launches PROphet® NSCLC Cancer Test in the United States
OncoHost has officially launched its PROphet NSCLC Test in the United States. The test provides clinicians with actionable clinical insights into optimal first-line therapeutic choices for advanced unresectable non-small lung cancer patients. It scans approximately 7,000 proteins in a patients blood plasma and delivers a report that predicts their clinical benefit from anti-PD-1/PD-L1 immunotherapy-based treatment plans. The PROphet NSCLC Test is supported by a blinded validation demonstrating its accuracy in predicting a patients clinical benefit and overall survival differences. OncoHost aims to improve patient care and treatment protocols with its precision diagnostics platform.
Customers
growth-positive
Oncohost partners with US research institutions to analyze resistance mechanisms in cancer
Oncohost Ltd. has partnered with Baylor Scott & White Research Institute and the Translational Genomics Research Institute (TGen) in a five-year study to analyze resistance mechanisms in cancer. The study aims to improve personalized cancer therapy by better understanding host response, patient microbiome, tumor DNA, and immune system activity in 350 patients with non-small cell lung cancer (NSCLC).
Partners
growth-positive
OncoHost Wins 2023 BIG Innovation Award for PROphet® Platform
OncoHosts PROphet platform has been named a winner in the healthcare category of the 2023 BIG Innovation Awards. PROphet is a first-of-its-kind platform that assesses patient response to treatment and provides personalized care. The platform scans proteins in a patients plasma to identify patterns that decode cancer resistance mechanisms. It assigns a PROphet score, which measures the predicted clinical benefit of treatment, and provides treatment considerations. OncoHost is a commercial-stage precision oncology company based in Israel and North Carolina. The company aims to overcome treatment resistance by understanding the patients unique response to therapy.
Customers
growth-positive
Baylor Scott & White Research Institute, TGen and OncoHost Announce New Research Study to Analyze Resistance Mechanisms in Lung Cancer
OncoHost, Baylor Scott & White Research Institute, and TGen have announced a new research study to analyze cancer resistance mechanisms using multiomics technologies. The study will utilize Baylor Scott & Whites Texas Immuno-Oncology Biorepository to analyze elements such as the host response, the patients microbiome, tumor DNA, and immune system activity. OncoHosts PROphet platform will be used to guide treatment decisions and identify resistance mechanisms. The study aims to improve patient outcomes and overall survival for patients with advanced cancer. OncoHosts PROphet platform is set to launch in the U.S. in the first quarter of 2023.
Partners
growth-positive
New Study Combines AI And Multiomics Analysis To Understand Cancer Resistance Mechanisms
OncoHost, in collaboration with Baylor Scott and White Health and the Translational Genomics Research Institute (TGen), is conducting a research study to analyze cancer resistance mechanisms using multiomics technologies. OncoHost has developed a precision oncology platform that guides treatment decisions and identifies resistance mechanisms. The study will utilize Baylor Scott and Whites biorepository to analyze resistance mechanisms in lung cancer patients. The study aims to identify early resistance to treatment using multiomics technologies. OncoHosts platform has shown promising results in predicting clinical benefit and identifying personalized drug combinations. The company plans to launch its PROphet® platform in the U.S. in 2023.
PartnersCustomers
growth-positive
OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023
OncoHost, a biotech company in the precision oncology space, is developing the PROphet platform, a precision oncology tool that enables personalized treatment for cancer patients. The platform uses high-throughput protein analysis to identify proteomic patterns that predict treatment response and resistance mechanisms. OncoHost plans to launch the PROphet test for non-small cell lung cancer (NSCLC) patients in the U.S. in February 2023. The company aims to address the clinical issue of treatment resistance and the lack of reliable biomarkers in oncology. The timing for innovation in biotech in the precision oncology space is ideal due to the plateau in current treatment efficacy, the increasing number of treatment combinations, the cost issues, and the availability of advanced AI and machine learning tools.
CustomersExpand
growth-positive
OncoHost to Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022
OncoHost, a global leader in precision oncology, has developed a predictive model for clinical benefit of immune checkpoint inhibitors in non-small cell lung cancer patients. The model is based on proteomic profiling of pre-treatment blood samples and machine learning analysis. It outperforms the existing PD-L1 biomarker in predicting clinical benefit probability at twelve months. The study was conducted using OncoHosts PROphet platform and will be presented at the Society for Immunotherapy of Cancers Annual Meeting. The model provides a decision-making tool for physicians on whether to administer immunotherapy alone or in combination with chemotherapy. OncoHost plans to launch its PROphet test in the U.S. for NSCLC patients. The company aims to improve patient outcomes in clinical oncology by understanding the patients unique response to therapy.
Customers
growth-positive
OncoHost Announces New Executive Appointments Ahead of Imminent Launch of its Precision Oncology Platform
OncoHost has announced two appointments to its executive team as it prepares for the launch of its AI-powered PROphet® Platform. The platform provides a proteomics-based decision support tool for patients with advanced cancer being treated with immunotherapy. The first test to be rolled out is for non-small cell lung cancer. The company aims to revolutionize cancer treatment by providing accurate response trajectory and personalized treatment strategies. James Whelan, a seasoned healthcare executive, joins the board of directors, while Chris Dingman, an oncology market expert, joins as chief commercial officer. The appointments will help guide the companys expansion in the US market. OncoHost combines life-science research and machine learning technology to develop personalized strategies for cancer therapy.
CustomersPartners
growth-positive
JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients
OncoHost, a global leader in next-generation precision oncology, published a peer-reviewed article highlighting the role of blood plasma proteomic profiling in assessing resistance in non-small cell lung cancer patients being treated with immune checkpoint inhibitors. The study used OncoHosts diagnostic platform, PROphet, to predict patient response to immunotherapy and identify resistance-associated processes. The results have the potential to improve personalized cancer therapy and overcome resistance to treatment. The article was authored by a team of Israeli and international scientists and oncologists. OncoHost is preparing for the launch of PROphet in the US and aims to transform cancer patient care.
Customers
Growth-Positive
OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology
OncoHost, a precision oncology company, has raised $35 million in a Series C funding round. The funds will be used to expand the companys ongoing multicenter PROPHETIC trial and support the imminent U.S. commercial launch of its precision oncology diagnostic solution. The funding round was led by ALIVE Israel HealthTech VC and included participation from Leumi Partners, Menora Mivtachim, and OurCrowd. OncoHosts PROphet® platform uses AI and proteomic analysis to provide early identification of an individuals responsiveness to cancer therapy and potential strategies to overcome treatment resistance.
InvestmentExpand
growth-positive
OncoHost Collaborates with Lung Biobank Heidelberg to Discover Lung Cancer Biomarkers - Biobanking.com
OncoHost, a leader in precision oncology, has announced a research collaboration with Lung Biobank Heidelberg, a member of BioMaterialBank Heidelberg (BMBH) and the German Center for Lung Research (DZL). The collaboration will involve the collection and integration of data to refine patient stratification and identify novel biomarkers and therapeutic targets, primarily for immunotherapy-treated non-small cell lung cancer (NSCLC) patients. OncoHost will work with Lung Biobank to collect blood samples, analyze them and share the data, with the aim of improving patient stratification methods in lung cancer.
PartnersExpand
growth-positive
OncoHost Publishes Data Identifying Predictive Signature for Response to Immunotherapy in Lung Cancer Patients
OncoHost, a global leader in precision oncology, has published a study identifying a predictive proteomic signature for patient response to immune checkpoint inhibitor therapy in non-small-cell lung carcinoma patients. The study demonstrates the potential clinical utility of OncoHosts AI-based platform, PROphet, in offering targeted treatment options and identifying new therapeutic strategies. The research was conducted in collaboration with several medical institutions. OncoHosts bioinformatic analysis and host response evaluation based on proteomic data can accurately predict patient outcomes. The study will be presented at the ESMO Virtual Congress 2021.
Customers
growth-positive
OncoHost Wins Frost & Sullivan 2021 Technology Innovation Leadership Award for Excellence in Best Practices
OncoHost has been awarded the Best Practices Technology Innovation Leadership Award in the AI-based precision oncology industry by Frost & Sullivan. The company has developed PROphet, a diagnostic platform that combines proteomic analysis with AI to predict patient response to treatment and identify resistance-associated processes. PROphet has shown high accuracy in predicting treatment outcomes in patients with non-small cell lung cancer and melanoma. OncoHost plans to launch PROphet in 2022 and expand its research to address more cancer indications. The article highlights the importance of OncoHosts technology in improving the success of cancer treatment and its potential impact in densely populated geographies with a high number of cancer cases and fewer therapeutic options.
Customers
growth-positive
OncoHost's Focus On The Patient Offers Precision Oncology To Combat Cancer
Israeli company OncoHost focuses on the host response to cancer therapy, seeking to personalize and modify care rather than develop new treatments. They measure changes in proteins in a patients blood to predict treatment response and identify resistance. OncoHost has launched eight clinical trial sites in the UK in collaboration with the NHS and has raised $8 million in a Series B funding round led by OurCrowd. The company is working with hospitals in Israel, the US, Germany, and Denmark. OncoHosts first major product, PROphet, combines proteomic analysis with AI to predict responses to immunotherapy treatments. The ongoing clinical trials have shown promising results. OncoHost plans to launch its first commercial site in the US and has other products in development.
CustomersPartnersInvestment
growth-positive
Israel's OncoHost, UK's NHS to study cancer patient responses to immunotherapies
Israel-based startup OncoHost will collaborate with the National Health Service (NHS) to set up eight clinical trial sites in the UK. The trials will focus on predicting the response of advanced melanoma and non-small cell lung cancer patients to immunotherapy treatment. OncoHosts diagnostic platform, PROphet, combines protein analysis with AI to predict patient response to immunotherapy and identify resistance to treatment. Previous studies have shown high accuracy in predicting patient response. The collaboration with the NHS will allow OncoHost to expand its research and enhance its technology. OncoHost plans to launch the PROphet software later this year and expand its research to other cancers.
PartnersExpand
growth-positive
OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform
OncoHost, a global leader in host response profiling for personalized cancer therapy, has completed an $8 million Series B funding round. The funding will support ongoing clinical trials, the opening of a US-based affiliate, and the upcoming launch of PROphet®, the companys machine learning-based Host Response Profiling platform. The funding round was led by OurCrowd, along with family offices and private investors. OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies for cancer patients. Their platform, PROphet®, analyzes proteomic changes in patient blood samples to predict patient response to immunotherapy and provide clinicians with potential combination strategies to overcome treatment resistance. PROphet® will be made available to healthcare providers to aid in treatment planning and decision-making.
Investment
growth-positive
OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board
OncoHost, a global leader in host response profiling for personalized cancer therapy, has announced that Professor Aaron Ciechanover, Nobel Prize winner in Chemistry, has joined the companys scientific advisory board. This addition is expected to improve OncoHosts research efforts in identifying effective personalized cancer treatments. Professor Ciechanovers expertise in protein biology and his innovative ideas will contribute to OncoHosts unique approach to host response analysis and overcoming therapy resistance. OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies for cancer therapy. Their Host Response Profiling platform analyzes proteomic changes in blood samples to monitor the patients response to therapy and predict individual patient outcomes. The company aims to maximize the success of cancer therapy and advance the development of novel therapeutic strategies.
Partners
growth-positive
OncoHost Offers New Hope For Cancer Sufferers
OncoHost, an Israeli company, is developing personalized strategies for cancer therapy using a proprietary proteomic analysis. The company aims to overcome the obstacle of treatment resistance in clinical oncology by understanding an individual patients unique response to therapy. OncoHosts abstract on plasma-based proteomic profiling for predicting response to immunotherapy in melanoma patients was accepted for presentation at the Society for Immunotherapy of Cancers Annual Meeting. The study was conducted in collaboration with the University of Connecticut, Yale Universitys Cancer Center, and the Technion Institute of Technology.
Customers
growth-positive
Israeli blood test offers better choices to fight cancer - Sponsored Content The Times of Israel
Israel-based startup OncoHost is developing a blood test called PROphet that identifies which cancer treatments are most likely to help specific patients. The system uses machine learning to analyze patterns of proteins in a patients blood plasma and predict the success of immunotherapy treatments. OncoHost has achieved about 90% accuracy in identifying patients who respond to particular treatments. The company is backed by OurCrowd and the U.S.-Israel Binational Industrial Research and Development (BIRD) Foundation. OncoHost aims to bring its technology to the market in late 2021 and plans to expand to other types of cancer.
Customers
growth-positive
Startup develops blood test that aims to undermine tumors' resilience
Israeli startup ONCOHOST is developing a blood test that can predict the effectiveness of cancer treatments on individual patients. The test measures the hosts response to treatment by analyzing plasma proteins in the blood. By understanding how the body repairs damage caused by treatment, physicians can adjust therapies to prevent tumor recurrence. The company is currently conducting clinical trials in Israel and is in negotiations to expand trials to other countries. The blood test has the potential to provide patients with up-to-date information about the expected efficacy of their therapy and options to modify it for better outcomes.
CustomersPartners
growth-positive
OncoHost and RayBiotech Awarded $1 Million Grant From the BIRD Foundation to Advance Precision Oncology for Patients Receiving Immunotherapy
OncoHost and RayBiotech have been awarded a $1 million grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation. The grant will support the development and clinical validation of host response testing for the early prediction of treatment responsiveness in non-small-cell lung carcinoma (NSCLC) patients undergoing immunotherapy. It will also be used to develop an automated slide assistance platform (ASAP) for reducing the time of large-scale protein processing. This partnership aims to enable personalized cancer therapy for patients.
InvestmentPartners
growth-positive
Israeli algorithm may predict if cancer patients will respond to treatment
Israeli company OncoHost has developed a method to analyze and predict individual patient responsiveness to immunotherapy treatments. By combining proprietary technology with proteomic analysis, OncoHost can predict how patients may respond to treatment, improving personalized cancer treatment plans. The company has opened a state-of-the-art proteomics laboratory in Israel and is running clinical trials to validate its algorithm. If successful, OncoHost will seek FDA approval.
CustomersPartners
growth-positive
First-Of-Its-Kind Lab To Improve Personalized Cancer Therapy Opens In Israel
OncoHost, an Israeli company, has opened a new proteomics laboratory to analyze the host response to cancer treatment. The lab aims to improve personalized cancer therapy by creating proteomic signatures and predicting individual patient responses to treatment. The lab is currently in research mode and uses a low volume of plasma to analyze more than 1,000 proteins. OncoHosts PROphet platform is used to identify key biological processes and proteins that drive response in cancer patients. The company believes that the combination of the new lab and their platform will provide value to the global oncology community and help address the challenges of immunotherapy for cancer.
Expand
growth-positive
OncoHost: Nature Reviews Cancer Article Outlines Host Response Analysis as New Tool for Precision Medicine in Oncology
OncoHost, a global leader in host response profiling for personalized cancer therapy, has published a review in Nature Reviews Cancer. The review, authored by Prof. Yuval Shaked, explores the host-mediated pro-tumorigenic response to cancer therapies. It discusses how the unique host response to different cancer treatments can promote therapy resistance and tumor progression. By focusing on the host response, OncoHost aims to improve understanding of how treatments influence tumor progression and identify treatments that may result in improved outcomes. OncoHost combines life-science research and advanced machine learning technologies to provide personalized treatment strategies based on proteomic analysis. The companys goal is to maximize the success of cancer therapy and reduce side effects.
Customers
OncoHost Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 50 |
| Team members | 13 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 16 classification IDs that could be used for matching.
OncoHost Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515644631 |
| Crunchbase | oncohost |
| Phone | +972-4-853-7558 |
| Creator | Hilla Gorokhovsky |
| Creator email | hilla.gorokhovsky@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-03T00:00:00.000Z |
| Created | 2018-08-09T00:00:00.000Z |
| Claimed | Yes |